- Report
- May 2025
- 193 Pages
Global
From €3111EUR$3,545USD£2,692GBP
€3457EUR$3,939USD£2,991GBP
- Report
- July 2024
- 150 Pages
Global
From €3905EUR$4,450USD£3,379GBP
- Clinical Trials
- April 2025
- 280 Pages
Global
From €2633EUR$3,000USD£2,278GBP
- Report
- June 2025
- 150 Pages
Global
From €2369EUR$2,699USD£2,049GBP
- Report
- May 2024
- 132 Pages
Global
From €5704EUR$6,499USD£4,935GBP
- Report
- May 2024
- 131 Pages
Global
From €5704EUR$6,499USD£4,935GBP
- Report
- May 2024
- 132 Pages
Global
From €5704EUR$6,499USD£4,935GBP
- Report
- October 2023
- 145 Pages
Global
From €2764EUR$3,150USD£2,392GBP
- Report
- April 2023
- 180 Pages
Global
From €2852EUR$3,250USD£2,468GBP
- Report
- August 2024
- 80 Pages
Japan
From €2611EUR$2,975USD£2,259GBP
€3072EUR$3,500USD£2,658GBP
- Report
- February 2024
- 360 Pages
Global
From €6977EUR$7,950USD£6,037GBP
- Report
- December 2023
- 140 Pages
Global
From €3124EUR$3,560USD£2,703GBP
€3905EUR$4,450USD£3,379GBP
- Report
- November 2020
- 199 Pages
Global
€3949EUR$4,500USD£3,417GBP
- Report
- July 2025
- 50 Pages
Global
From €2326EUR$2,650USD£2,012GBP

Bimatoprost is a medication used to treat glaucoma and other optical disorders. It is a prostaglandin analog, meaning it works by increasing the outflow of fluid from the eye, reducing intraocular pressure. Bimatoprost is available as a topical ophthalmic solution, and is the only prostaglandin analog approved for the treatment of glaucoma and ocular hypertension. It is also used to treat hypotrichosis, a condition characterized by inadequate or thinning eyelashes.
Bimatoprost is a widely used medication in the optical disorders drugs market. It is the most commonly prescribed prostaglandin analog for glaucoma and ocular hypertension, and is also used off-label for other conditions. Bimatoprost is generally well-tolerated, with few side effects.
Some companies in the Bimatoprost market include Allergan, Sun Pharmaceuticals, and Pfizer. Show Less Read more